Hormone Replacement Therapy HRT TRT

by Dr. Randy Smith of Antiaging Atlanta

While Testosterone Hormone Replacement Therapy in men may cause an elevated Hg/Hct the increased risk of a VTE venothromboembolism is inconclusive in spite ofr the FDA warning. If there is increased risk of VTE it is alieviated with therapeutic phlebotomy.

 2015 Apr;3(2):101-112. doi: 10.1002/smrj.43. Epub 2015 Dec 2.

Erythrocytosis and Polycythemia Secondary to Testosterone Replacement Therapy in the Aging Male.



Testosterone replacement therapy (TRT) is a common treatment for hypogonadism in aging males. Men with low to low-normal levels of testosterone have documented benefit from hormone replacement. Recent meta-analyses have revealed that increases in hemoglobin (Hb) and hematocrit (Hct) are the variants most commonly encountered. Clinically, this response is described as erythrocytosis or polycythemia secondary to TRT. However, the recent Food and Drug Administration warning regarding the risk for venothromboembolism (VTE) has made the increases in Hb and Hct of more pertinent concern. The risks associated with androgen replacement need further examination.


To review the available literature on erythrocytosis and polycythemia secondary to TRT. To discuss potential etiologies for this response, the role it plays in risk for VTE, and recommendations for considering treatment in at-risk populations.


A literature review was performed through PubMed regarding TRT and erythrocytosis and polycythemia.


To assess the mechanisms of TRT-induced erythrocytosis and polycythemia with regard to basic science, pharmacologic preparation, and route of delivery. To review Hct and risk for thrombotic events. To offer clinical suggestions for therapy in patients at risk for veno-thrombotic events.


Men undergoing TRT have a 315% greater risk for developing erythrocytosis (defined as Hct > 0.52) when compared with control. Mechanisms involving iron bioavailability, erythropoietin production, and bone marrow stimulation have been postulated to explain the erythrogenic effect of TRT. The association between TRT-induced erythrocytosis and subsequent risk for VTE remains inconclusive.


All TRT formulations cause increases in Hb and Hct, but injectables tend to produce the greatest effect. The evidence regarding the risk for VTE with increased Hct is inconclusive. For patients with risk factors for veno-thrombotic events, formulations that provide the smallest effect on blood parameters hypothetically provide the safest option. Further trials are needed to fully evaluate the hematological side effects associated with TRT. Jones SD Jr, Dukovac T, Sangkum P, Yafi FA, and Hellstrom WJG. Erythrocytosis and polycythemia secondary to testosterone replacement therapy in the aging male. Sex Med Rev 2015;3:101-112.

Copyright © 2015 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.


Erythrocytosis; Hematocrit; Late‐Onset Hypogonadism; Polycythemia; Testosterone; Testosterone Deficiency; Testosterone Replacement Therapy

  Personal Message from Dr. Smith

My primary goal at AntiagingAtlanta is to enhance your quality of life through providing a comprehensive approach to antiaging medicine.

I am committed to providing you with the best Antiaging Medicine program available.

Call me today and schedule your Antiaging Medicine evaluation.


Dr. Randy Smith



Antiaging Atlanta
12600 Deerfield Parkway
Suite 100
Alpharetta, Georgia 30004

Phone: 678-566-3602

Call today today and speak with Dr. Smith to schedule your personal Agntiaging Medicine evaluation.

Getting Started

To unsubscribe to our newsletter email Dr. Smith at:

Dr. Smith